JAPANESE DERMATOLOGICAL ASSOCIATION
THE JOURNAL OF DERMATOLOGY

doi: 10.1111/j.1346-8138.2010.01059.x

Journal of Dermatology 2011; **38**: 261–266

REVIEW ARTICLE

Sorafenib-associated hand–foot syndrome in Japanese patients

Masafumi IIJIMA,[1] Koichi FUKINO,[2] Masatoshi ADACHI,[2] Taiji TSUKAMOTO,[3] Masaru MURAI,[4] Seiji NAITO,[5] Hironobu MINAMI,[6] Junji FURUSE,[7] Hideyuki AKAZA[8]

[1]Department of Dermatology, Showa University School of Medicine, [2]Bayer Yakuhin Ltd, Osaka, [3]Department of Urology, Sapporo Medical University School of Medicine, Sapporo, [4]International Goodwill Hospital, Yokohama, [5]Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, [6]Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, [7]Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, Tokyo, and [8]Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan

ABSTRACT

Sorafenib (Nexavar) is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis, having encouraging efficacy and tolerability in patients with metastatic renal cell carcinoma (RCC) and other tumors. However, hand–foot syndrome (HFS), a frequently reported adverse event under sorafenib treatment, sometimes causes interruption of the treatment or dose reduction. This study was conducted to review sorafenib-associated HSF in Japanese patients, to facilitate improvement of the management of HFS in clinical practice. We reviewed the combined results on HFS in three sorafenib studies in Japanese patients: (A) a phase II study of metastatic renal cell carcinoma; (B) a phase I study of solid tumor; and (C), phase I study of hepatocellular carcinoma. Severity of HFS was graded as 1–3 based on the modified grading scale of National Cancer Institute – Common Toxicity Criteria version 2.0 and Common Terminology Criteria for Adverse Events version 3.0. A total of 189 patients were included for analyses. The incidence of all-grade HFS was 51% (55% in A, 39% in B and 44% in C), and the incidence of grade 3 HFS was 7% (9% in A, 0% in B and 7% in C). Incidence of HFS seemed dose-dependent. These events were observed within 3–9 weeks after initiation of sorafenib treatment. The majority of HFS was manageable with symptomatic treatment and HFS caused permanent discontinuation of sorafenib in only one patient (in study A). The incidence of sorafenib-associated HFS is high compared to other adverse events. However, the present analyses showed that HFS under sorafenib treatment is well manageable in Japanese patients.

Key words: carcinoma, clinical trial, hand–foot skin reaction, Japanese patients, renal cell, sorafenib.

INTRODUCTION

Sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ, USA/Onyx Pharmaceuticals, Inc., Emeryville, CA, USA) is a novel, orally available, multi-kinase inhibitor that inhibits Raf-1 and receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1/-2/-3, platelet-derived growth factor receptor-β (PDGFR-β), c-Kit, Flt-3 and RET.[1,2] Sorafenib has been approved for use in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) in many countries and regions, including the EU, USA and Japan.

Therapeutic drugs of new chemical entities are usually associated with new types of adverse events, which are sometimes serious. As with other antineoplastic agents, sorafenib is associated with many side-effects, including diarrhea, hypertension

Correspondence: Masafumi Iijima, M.D., Ph.D., Department of Dermatology, Showa University School of Medicine, Tokyo, Japan. Email: miijima@med.showa-u.ac.jp
Received 11 May 2010; accepted 10 June 2010.

and dermatological toxicities. In a phase II study in Japan using sorafenib for patients with metastatic renal cell cancer, dermatological changes including hand–foot syndrome (HFS, or hand–foot skin reaction; HFSR) and rash/desquamation were reported in more than 45% of patients, with HFS among the most frequent adverse manifestations.[3] Although sorafenib-induced HFS is usually not a life-threatening side-effect, it affects the quality of life in a significant manner and can be complicated by infection, pain and limitation of activities of daily living (ADL). In addition, it is a dose-limiting toxicity, and may lead to compromised efficacy because of dose reduction.[4]

To facilitate better management of the risk of HFS in patients receiving sorafenib, we have conducted a review of the results of clinical trials conducted in Japan in which sorafenib was used as a single agent.

METHODS

Data sources

For the present analyses, we reviewed the results of the following three clinical trials conducted in Japanese patients;

1 Sorafenib phase II study in RCC (study A) was a non-randomized, open-label study of patients with metastatic RCC who had received nephrectomy and failed one or more regimen of cytokine-containing therapy. The primary end-point was response rate. Patients continuously received sorafenib 400 mg twice daily. A total of 129 patients (median age, 63 years) were considered valid for intention-to-treat analyses.[3]
2 Sorafenib phase I study in solid tumor (study B) was a phase I study of patients with solid tumor, to investigate pharmacokinetics, toxicity profile and preliminary antitumor activities of sorafenib in Japanese patients. Thirty-one patients with refractory solid tumors were treated continuously with sorafenib 100–600 mg twice daily, following 7 days washout after receiving a single dosing.[5]
3 Sorafenib phase I study in HCC (study C) was a phase I study of patients with unresectable HCC of Child–Pugh classification A or B, to investigate pharmacokinetics, toxicity profile and preliminary antitumor activities. The patients received either sorafenib 200 or 400 mg twice daily continuously, following a 7-day washout period after receiving a single dosing.[6]

Signed informed consents had been obtained from all the patients in the three clinical trials before the study treatments started. The studies were approved by the Institutional Review Boards and/or Ethical Committee at each center with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations.

Evaluation of HFS

Incidence and severity of skin toxicities, including HFS, were evaluated for studies A, B and C. In particular, timing of onset of HFS events, and incidence and severity of HFS with respect to patient characteristics were analyzed for study A. Severity of HFS was recorded according to the modified National Cancer Institute – Common Toxicity Criteria and Common Terminology Criteria for Adverse Events version 3.0 (Table 1).[7] Macroscopic photos of HFS in Japanese patients treated with sorafenib are presented in Figure 1.

RESULTS

Incidence and severity of HFS in the three clinical studies

A total of 189 patients treated with sorafenib monotherapy from the three clinical trials were

Table 1. Grading of hand–foot syndrome†

Grade	Clinical characteristics
1	Numbness, dysesthesia/paresthesia, tingling, painless swelling, or erythema of the hands and/or feet and/or discomfort, which does not disrupt normal activities.
2	Painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient's activities.
3	Moist desquamation, ulceration, blistering or severe pain of the hands and/or feet and/or severe discomfort that causes the patient to be unable to work or perform activities of daily living.

†Modified criteria based on National Cancer Institute – Common Toxicity Criteria version 2.0 and Common Terminology Criteria for Adverse Events version 3.0.



Figure 1. Photos of hand–foot syndrome (HFS) in Japanese patients treated with sorafenib. (a,d) Grade 1, (b,e) grade 2 and (c,f) grade 3. In grade 1 HFS, only mild erythema is found on the palmar and the plantar surface (brackets in a,d). In grade 2 HFS, peeling is observed at palmar and plantar pressure areas in addition to erythema (arrows in b,e). In grade 3 HFS, blisters with severe dermatitis around them are observed at palmar and plantar pressure area (arrowheads in c,f).

Table 2. Patient characteristics

	Study A (Akaza *et al.*, 2007)	Study B (Minami *et al.*, 2008)	Study C (Furuse *et al.*, 2008)
No. of patients	131[†]	31	27
Sex (*n*)			
Male	102	21	25
Female	29	10	2
Age (years)			
Median	63	63	70
Range	30–83	32–72	48–79
ECOG-PS (*n*)			
0	102	8	27
1	29	23	0
Cancer type (*n*)	Renal cell (131)	Non-small lung (10) Colorectal (6) Renal cell (3) Gastric (2) Others (10)	Hepatocellular (27)

[†]Number of patients considered valid for safety study was 131, while that for intent-to-treat was 129. ECOG-PS, Eastern Cooperative Oncology Group – performance status.

available for analyses. Patient characteristics of each of the three clinical trials are summarized in Table 2. No HFS was listed as a baseline characteristic in any of the patients. Underlying malignancies for the three studies included renal cell cancer, non-small cell lung cancer, hepatocellular cancer, and other cancers. Among patients receiving sorafenib, the summary incidence of all-grade HFS was 51% (55% in study A, 39% in B and 44% in C) and that of grade 3 HFS was 7% (9% in study A, 0% in B and 7% in C). HFS was one of the most frequently observed skin toxicities, along with rash/desquamation, in each of the three clinical trials (Table 3). In studies B and C, where sorafenib was administrated at different doses, dose

Table 3. Incidence of skin toxicities, including hand–foot syndrome (HFS)

	Study A (Akaza *et al.*, 2007)	Study B (Minami *et al.*, 2008)	Study C (Furuse *et al.*, 2008)	Total
	n = 131	*n* = 31	*n* = 27	*n* = 189
Adverse events	*n* (%)			
HFS				
Any grade	72 (55)	12 (39)	12 (44)	96 (51)
Grade 3	12 (9)	0	2 (7)	14 (7)
Alopecia				
Any grade	51 (39)	8 (26)	5 (19)	64 (34)
Grade 3/4	0	0	0	0
Dry skin				
Any grade	4 (3)	7 (23)	3 (11)	14 (7)
Grade 3/4	0	0	0	0
Pruritus				
Any grade	14 (11)	5 (16)	8 (30)	27 (14)
Grade 3/4	0	0	0	0
Rash/desquamation				
Any grade	49 (37)	19 (61)	15 (56)	83 (44)
Grade 3/4	5 (4)	0	2 (7)	7 (4)

Table 4. Incidence of hand–foot syndrome at different dose of sorafenib

	Study A (Akaza *et al.*, 2007)	Study B (Minami *et al.*, 2008)	Study C (Furuse *et al.*, 2008)
Dose	*n* = 131	*n* = 31	*n* = 27
100 mg b.i.d.	–	0/3 (0%)	–
200 mg b.i.d.	–	3/15 (20%)	4/13 (31%)
400 mg b.i.d.	72/131 (55%)	3/6 (50%)	8/14 (57%)
600 mg b.i.d.	–	6/7 (86%)	–

dependency for the incidence of HFS was suggested (Table 4). Incidence at 400 mg b.i.d. was similar among the three studies.

Timing of onset

An analysis of cumulative event rates of HFS in study A revealed that HFS occurred at the early stage of sorafenib treatment. Of the 72 patients suffering from sorafenib-related HFS, 43 patients developed new-onset HFS during the first 3 weeks of treatment, 14 patients at week 6, nine patients at week 9, and fewer thereafter (Fig. 2). A similar pattern was observed in the other clinical trials (data not shown).

HFS and patient characteristics

Incidence and severity of HFS in study A were summarized with respect to patient characteristics, including sex, age, Eastern Cooperative Oncology Group – performance status (ECOG-PS) and bodyweight (Table 5). None of the patient characteristics analyzed showed any apparent association with the incidence of all-grade HFS. Female sex (21% vs 6%) and ECOG-PS 0 (11% vs 3%) seemed to have a tendency to be related to grade 3 HFS; however, as there were great differences in patient numbers between women and men (29 vs 102) and between ECOG-PS 0 and 1 (102 vs 29), further investigations are needed to discern the relationship between these patient characteristics and severity of HFS.



Figure 2. Timing of onset and cumulative event rate of hand–foot syndrome (HFS) in Japanese patients treated with sorafenib. HFS occurred at the early stage of sorafenib treatment. Out of 72 patients who had HFS in study A, 43 patients developed HFS during the first 3 weeks.

Table 5. Incidence of hand–foot syndrome by patient characteristics in study A

Patient characteristics	All grade *n* (%)	Grade 3 *n* (%)
Sex		
Male (*n* = 102)	51 (50)	6 (6)
Female (*n* = 29)	21 (72)	6 (21)
Age (years)		
<45 (*n* = 7)	3 (43)	0
45–64 (*n* = 68)	41 (60)	6 (9)
65–74 (*n* = 45)	20 (44)	4 (9)
≥75 (*n* = 11)	8 (73)	2 (18)
ECOG-PS		
0 (*n* = 102)	56 (55)	11 (11)
1 (*n* = 29)	16 (55)	1 (3)
Bodyweight (kg)		
<60 (*n* = 52)	30 (58)	5 (10)
60–69 (*n* = 52)	25 (48)	5 (10)
70–79 (*n* = 19)	13 (68)	2 (11)
≥80 (*n* = 7)	4 (57)	0

ECOG-PS, Eastern Cooperative Oncology Group – performance status.

Dose modification of sorafenib caused by HFS

In study A, HFS was the leading cause of dose interruption (14 patients, 11%) and dose reduction (12 patients, 9%) of sorafenib. HFS caused permanent discontinuation of sorafenib treatment in one patient (1%) in study A, but none in studies B and C.

DISCUSSION

The present analyses demonstrated that sorafenib was associated with a significantly increased risk of HFS in Japanese patients being treated for renal cell cancer and other solid tumors. The incidence of all-grade HFS (51%) was slightly higher than those reported overseas in phase III trials for RCC (30%) and HCC (21%), but the incidence of grade 3 HFS (7%) was comparable with those reported overseas in phase III trials (6% in RCC and 8% in HCC) or the systematically reviewed data of HFS incidence.[4,8,9] This suggests that there is no apparent racial difference in HFS incidence between white and Japanese subjects.

Hand–foot syndrome itself is not a new manifestation under treatment with chemotherapeutic agents. It has been reported that HFS is associated with several systemic chemotherapeutic agents including 5-fluorouracil, capecitabine, doxorubicin and others.[10–13] On the one hand, HFS observed in sorafenib treatment shares many features with conventional HFS (i.e. palm–plantar distribution, dose dependency, tenderness and impact on consistent antineoplastic therapy). On the other hand, it was reported that HFS associated with sorafenib differed from classical-type HFS in clinical and histological characteristics (sorafenib HFS is characterized by thick, well-defined hyperkeratotic lesions frequently affecting digit flexural locations).[14–16]

The pathogenesis of sorafenib-induced HFS is uncertain; however, for HFS observed in other systemic chemotherapeutic agents,[10] some hypotheses have been proposed: (i) excretion of cytotoxic drugs in sweat causes palms and soles to be more prone to HFS due to the higher number of eccrine sweat glands in the extremities, while areas with apocrine sweat glands are not affected;[11,12] (ii) a more mechanical effect of direct pressure to the areas affected, because sorafenib is a tyrosine kinase inhibitor affecting both VEGF and PDGF, the capillary endothelium may therefore be the first tissues damaged by sorafenib, especially the hand and foot surfaces which are under direct pressure from walking, hand washing or other daily use;[13] (iii) a direct effect of sorafenib on receptors located on the eccrine glands themselves; and (iv) alteration of keratinocytes by inhibition of the c-Kit receptor, because it has been shown that the c-Kit ligand is expressed on human keratinocytes,[17] and it is reasonable that the direct inhibiting effect of sorafenib on c-Kit may be toxic to the keratinocytes. In any case, dose-dependency of sorafenib-associated HFS does not suggest an allergic mechanism but a toxic one.[18] The significant incidence and risk demonstrated in this study underscore a need for additional basic and clinical studies to investigate the pathogenesis and treatment of sorafenib-associated HFS.

Although we investigated the relationships between patient characteristics and HFS, we found no such characteristic as related to HFS. Therefore, physicians need to pay attention to prevention and management of HFS in all sorafenib-treated patients. Recently, avoiding mechanical skin stimuli, moisturizing skin and manicure/pedicure of hyperkeratinized skin have been recommended to prevent occurrence and worsening of HFS.[15] In the present review, female and ECOG-PS 0 patients showed a higher tendency to be related to grade 3 HFS than male and ECOG-PS 1 patients, suggesting that the former patients may be more exposed to mechanical stimuli in daily life, such as washing dishes with hot water or active walking. As for topical treatment for prevention and management of HFS, moisturizing creams, urea- or salicylic acid-containing topical treatments for chemical exfoliation of skin, and topical corticosteroids for more severe inflammation with painful erythema, are recommended according to the skin symptoms.[15]

Once HFS is observed, dose modification of sorafenib is one of the options in management of HFS, along with physical and chemical therapies. Although the first step in dose modification of sorafenib was dose interruption in the three clinical trials, recently published articles recommend the treatment algorithm of HFS in which the first step in dose modification of sorafenib should be dose reduction instead of dose interruption.[16,19] In order to fulfill the antitumor effect of sorafenib, it is important to

maintain sorafenib exposure. For that purpose, it is reasonable to reduce sorafenib dose instead of interrupting sorafenib treatment as the first step of dose modification.

In conclusion, the present review has demonstrated that sorafenib was associated with a relatively high risk of developing HFS, and HFS was one of the most frequently observed skin toxicities along with rash/desquamation in Japanese patients. As none of the baseline patient characteristics was predictive of HFS, physicians should pay attention to prevention and management of HFS in all sorafenib-treated patients in order to avoid treatment interruption/discontinuation of sorafenib due to HFS.

ACKNOWLEDGMENT

The clinical trials reviewed here were supported by Bayer Yakuhin, Osaka, Japan.

REFERENCES

1 Wilhelm SM, Carter C, Tang L *et al.* BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res* 2004; **64**: 7099–7109.
2 Carlomagno F, Anaganti S, Guida T *et al.* BAY 43-9006 inhibition of oncogenic RET mutants. *J Natl Cancer Inst* 2006; **98**: 326–334.
3 Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. *Jpn J Clin Oncol* 2007; **37**: 755–762.
4 Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. *Acta Oncol* 2008; **47**: 176–186.
5 Minami H, Kawada K, Ebi H *et al.* Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. *Cancer Sci* 2008; **99**: 1492–1498.
6 Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. *Cancer Sci* 2008; **99**: 159–165.
7 National Cancer Institute (NCI). *Common Toxicity Criteria v2.0 and Common Terminology Criteria for Adverse Events v3.0.* [Accessed 2 July 2009.] Available from http://ctep.cancer.gov/reporting/ctc.html
8 Escudier B, Eisen T, Stadler WM *et al.* Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med* 2007; **356**: 125–134.
9 Llovet JM, Ricci S, Mazzaferro V *et al.* Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378–390.
10 Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. *J Clin Oncol* 1998; **16**: 3537–3541.
11 Mrozek-Orlowski ME, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. *Oncol Nurs Forum* 1999; **26**: 753–762.
12 Jacobi U, Waibler E, Schulze P *et al.* Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? *Ann Oncol* 2005; **16**: 1210–1211.
13 Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). *Ann Oncol* 2007; **18**: 1159–1164.
14 Robert C, Soria JC, Spatz A *et al.* Cutaneous side-effects of kinase inhibitors and blocking antibodies. *Lancet Oncol* 2005; **6**: 491–500.
15 Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. *J Am Acad Dermatol* 2009; **60**: 299–305.
16 Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. *Arch Dermatol* 2008; **144**: 886–892.
17 Morita E, Lee DG, Sugiyama M, Yamamoto S. Expression of c-kit ligand in human keratinocytes. *Arch Dermatol Res* 1994; **286**: 273–277.
18 Azad NS, Aragon-Ching JB, Dahut WL *et al.* Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. *Clin Cancer Res* 2009; **15**: 1411–1416.
19 Lacouture ME, Wu S, Robert C *et al.* Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. *Oncologist* 2008; **13**: 1001–1011.

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Hedy L Kindler, Tatsuya Ioka, Dirk J Richel, Jaafar Bennouna, Richard Létourneau, Takuji Okusaka, Akihiro Funakoshi, Junji Furuse, Young Suk Park, Shinichi Ohkawa, Gregory M Springett, Harpreet S Wasan, Peter C Trask, Paul Bycott, Alejandro D Ricart, Sinil Kim, Eric Van Cutsem

Lancet Oncol 2011; 12: 256–62
Published Online February 8, 2011
DOI:10.1016/S1470-2045(11)70004-3

See Comment page 206

University of Chicago Comprehensive Cancer Center, Chicago, IL, USA (H L Kindler MD); Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan (T Ioka MD); Academic Medical Centre, University of Amsterdam, Internal Medicine/Oncology, Amsterdam, Netherlands (D J Richel MD); Medical Oncology Services, Centre Rene Gauducheau, Nantes, France (J Bennouna MD); Centre Hospitalier, Universite de Montreal, Montreal, QC, Canada (R Létourneau MD); National Cancer Center Hospital, Tokyo, Japan (T Okusaka MD); National Kyushu Cancer Center, Department of Gastroenterology, Fukuoka, Japan (A Funakoshi MD); National Cancer Center Hospital East, Chiba, Japan (J Furuse MD); Divisions of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (Y S Park MD); Kanagawa Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology, Yokohama, Japan (S Ohkawa MD); H Lee Moffitt Cancer Center and Research Institute, Department of Gastrointestinal Oncology, WCB-GI Program, Tampa, FL, USA (G M Springett MD); Hammersmith Hospital, Department of Cancer Medicine, London, UK (H S Wasan MB); Pfizer Oncology, New London, CT, USA (P C Trask PhD); Pfizer Oncology, Pfizer Global Research and Development,

Summary

Background **Axitinib is a potent, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. A randomised phase 2 trial of gemcitabine with or without axitinib in advanced pancreatic cancer suggested increased overall survival in axitinib-treated patients. On the basis of these results, we aimed to assess the effect of treatment with gemcitabine plus axitinib on overall survival in a phase 3 trial.**

Methods **In this double-blind, placebo-controlled, phase 3 study, eligible patients had metastatic or locally advanced pancreatic adenocarcinoma, no uncontrolled hypertension or venous thrombosis, and Eastern Cooperative Oncology Group performance status 0 or 1. Patients, stratified by disease extent (metastatic *vs* locally advanced), were randomly assigned (1:1) to receive gemcitabine 1000 mg/m² intravenously on days 1, 8, and 15 every 28 days plus either axitinib or placebo. Axitinib or placebo were administered orally with food at a starting dose of 5 mg twice a day, which could be dose-titrated up to 10 mg twice daily if well tolerated. A centralised randomisation procedure was used to assign patients to each treatment group, with randomised permuted blocks within strata. Patients, investigators, and the trial sponsor were masked to treatment assignments. The primary endpoint was overall survival. All efficacy analyses were done in all patients assigned to treatment groups for whom data were available; safety and treatment administration and compliance assessments were based on treatment received. This study is registered at ClinicalTrials.gov, number NCT00471146.**

Findings **Between July 27, 2007, and Oct 31, 2008, 632 patients were enrolled and assigned to treatment groups (316 axitinib, 316 placebo). At an interim analysis in January, 2009, the independent data monitoring committee concluded that the futility boundary had been crossed. Median overall survival was 8·5 months (95% CI 6·9–9·5) for gemcitabine plus axitinib (n=314, data missing for two patients) and 8·3 months (6·9–10·3) for gemcitabine plus placebo (n=316; hazard ratio 1·014, 95% CI 0·786–1·309; one-sided p=0·5436). The most common grade 3 or higher adverse events for gemcitabine plus axitinib and gemcitabine plus placebo were hypertension (20 [7%] and 5 [2%] events, respectively), abdominal pain (20 [7%] and 17 [6%]), fatigue (27 [9%] and 21 [7%]), and anorexia (19 [6%] and 11 [4%]).**

Interpretation **The addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer. These results add to increasing evidence that targeting of VEGF signalling is an ineffective strategy in this disease.**

Funding **Pfizer.**

Introduction

The prognosis for patients with advanced pancreatic adenocarcinoma is poor, and gemcitabine, the standard of care, offers only slight benefit.[1,2] Despite extensive research, combination regimens with gemcitabine and cytotoxic or molecularly targeted agents have not significantly improved outcomes compared with gemcitabine monotherapy.[3] The addition of erlotinib to gemcitabine resulted in a significant but very small improvement in overall survival.[3,4] There is a pressing need for new treatment options for this disease.

Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.[5] A randomised phase 2 study[6] of 103 patients with locally advanced and metastatic pancreatic adenocarcinoma showed an improvement in median overall survival (6·9 *vs* 5·6 months; hazard ratio [HR] 0·71, 95% CI 0·44–1·13) and a greater 1-year survival (37% *vs* 24%) for axitinib plus gemcitabine versus gemcitabine alone. Although not significant, the apparent increase in survival in the combination group provided the rationale for a larger phase 3 study of this regimen. We aimed to assess overall survival in patients with advanced pancreatic cancer treated with gemcitabine plus axitinib versus gemcitabine plus placebo.

Methods

Study design and patients

We undertook a phase 3, randomised, double-blind, global, multicentre, two-group study. Eligible patients were at least 18 years old with histologically or cytologically confirmed metastatic or locally advanced pancreatic adenocarcinoma not amenable to curative resection. Patients were required to have adequate bone marrow, hepatic, and renal function (including urine protein <2 g/24 h); an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and no uncontrolled hypertension (two baseline blood pressure readings ≤140/90 mm Hg). Patients with documented

invasion of adjacent hollow organs were excluded. Adjuvant therapy that did not contain gemcitabine was allowed if 4 weeks or longer had passed since the last dose; previous radiation was allowed if there was disease outside the radiation port. Additional exclusion factors included: previous treatment with VEGF or VEGF receptor inhibitors; previous systemic chemotherapy for locally advanced or metastatic disease; use of a thrombolytic agent within 1 month of treatment; central lung lesions involving major blood vessels; recent haemoptysis, myocardial infarction, symptomatic congestive heart failure, cerebrovascular accident, transient ischaemic attack, deep-vein thrombosis, or pulmonary embolism in the past 12 months; peptic ulcer disease needing treatment in the past 6 months; active seizures or gastrointestinal bleeding; malabsorption syndromes; present use of potent cytochrome P450 (CYP) 3A4 inhibitors or CYP3A4 or CYP1A2 inducers; or major surgery within 4 weeks.

The study was undertaken with institutional review board approval and in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, as well as applicable local laws and regulatory requirements. All patients provided written informed consent.

Randomisation and masking

Patients were stratified by disease extent (metastatic *vs* locally advanced) and randomly allocated in a 1:1 ratio to receive gemcitabine plus either axitinib or placebo. A centralised randomisation procedure (interactive voice randomisation system accessible via telephone or internet) was used to assign patients to each treatment group, with randomised permuted blocks within strata. Randomisation was not done by centre, but by stratification category, and use of blocked randomisation made guessing of the next treatment assignment within a block almost impossible. Patients, investigators, and the trial sponsor were masked to treatment assignments.

Procedures

All patients received gemcitabine 1000 mg/m^2 intravenously during 30 min on days 1, 8, and 15 of each 4-week treatment cycle until disease progression, unacceptable toxic effects, or withdrawal of consent. Dose reductions to 750 mg/m^2, 550 mg/m^2, and 425 mg/m^2 were allowed for management of adverse events. Gemcitabine was discontinued in patients needing a dose interruption longer than 4 weeks or a dose reduction to less than 425 mg/m^2.

All patients also received either axitinib or placebo, administered orally with food at a starting dose of 5 mg twice a day, which was continued until disease progression, unacceptable toxic effects, or withdrawal of consent. Stepwise dose increases to 7 mg and then 10 mg twice a day were allowed in the absence of axitinib-related or placebo-related grade 3 or higher adverse events for consecutive 2-week periods in patients with blood pressure 150/90 mm Hg or lower who were not receiving antihypertensive drugs. Dose reductions to 3 mg or 2 mg twice daily were allowed for management of adverse events. In patients with systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 100 mm Hg, new or additional antihypertensive treatment was initiated and axitinib or placebo was continued. For patients on maximum antihypertensive treatment, the axitinib or placebo dose was reduced one level. For systolic blood pressure higher than 160 mm Hg or diastolic blood pressure higher than 105 mm Hg, antihypertensive treatment was adjusted, and axitinib or placebo dosing was interrupted and resumed at one lower dose level once blood pressure was lower than 150/100 mm Hg. If proteinuria of 2 g per day or higher occurred, axitinib or placebo dosing was interrupted and resumed at one lower dose level once proteinuria less than 2 g per day was recorded. For all other grade 3 axitinib-related or placebo-related non-haematological adverse events, the axitinib or placebo dose was decreased by one level. For grade 4 axitinib-related or placebo-related non-haematological adverse events or grade 4 haematological adverse events (except lymphopenia), dosing was interrupted and resumed at one lower dose level when the adverse event improved to grade 2 or lower. Treatment was discontinued if a dose interruption for longer than 4 weeks or a dose reduction to less than 2 mg twice a day was needed. If either gemcitabine or axitinib/placebo was interrupted or withdrawn, the remaining therapy was continued.

CT scans were obtained at screening, every 8 weeks during the study, and at follow-up 28 days after the last dose in patients who discontinued without progressive disease. Tumour response was assessed using the Response Evaluation Criteria in Solid Tumours (RECIST).[7] Safety was monitored by physical examination, urinalysis, haematology, and clinical chemistry tests; assessment of ECOG performance status; and adverse event reporting, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. An independent data monitoring committee reviewed accumulating unmasked safety and survival data during the study. Blood pressure was monitored in the clinic at baseline, on days 1, 8, and 15 of each 4-week treatment cycle, and at follow-up. Blood pressure was also measured and recorded in diaries by patients before each dose of axitinib or placebo. Thyroid-stimulating hormone (TSH) concentrations were evaluated at baseline, every 2 weeks for the first 6 weeks, and every 8 weeks thereafter.

The primary endpoint was overall survival; secondary endpoints included progression-free survival, objective response rate, duration of response, safety, and health-related quality of life. Health-related quality of life, pancreatic cancer-specific symptoms, pain, and health status were measured with the European Organisation for the Research and Treatment of Cancer quality of life questionnaire–core 30 (QLQ-C30) and pancreatic cancer module (QLQ-PAN26) at baseline, on day 1 of each treatment cycle, and 28 days after the last dose.[8,9]

La Jolla Laboratories, San Diego, CA, USA (P Bycott PhD, A D Ricart MD, S Kim MD); **and University Hospital Gasthuisberg/Leuven, Department of Digestive Oncology, Leuven, Belgium** (E Van Cutsem MD)

Correspondence to:
Dr Hedy L Kindler, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA
hkindler@medicine.bsd.uchicago.edu



Figure 1: **Trial profile**
*Data missing from database at time of analysis for two patients.

	Axitinib plus gemcitabine (n=314)*	Placebo plus gemcitabine (n=316)
Median age (years)	61 (34–84)	62 (35–89)
Sex		
Male	191 (61%)	188 (59%)
Female	123 (39%)	128 (41%)
ECOG performance status		
0	147 (47%)	158 (50%)
1	162 (52%)	154 (49%)
Missing	5 (2%)	4 (1%)
Disease extent		
Locally advanced	77 (25%)	73 (23%)
Metastatic	226 (72%)	227 (72%)
Missing	11 (4%)	16 (5%)
Metastatic sites		
Liver	146/264 (55%)	135/263 (51%)
Lung	63/264 (24%)	57/263 (22%)
Peritoneum	16/264 (6%)	20/263 (8%)
Previous adjuvant chemotherapy†	12 (4%)	12 (4%)
Mean QLQ-30 global health status/QoL score	54·2 (22·3)‡	57·1 (23·1)§

Data are median (range), n/N (%), or mean (SD). Some data are missing from this table because they were derived from case report forms. ECOG=Eastern Cooperative Oncology Group. QLQ-C30=European Organisation for the Research and Treatment of Cancer quality of life questionnaire, core 30. QoL=quality of life. *Data missing from database at time of analysis for two patients. †Includes neoadjuvant therapy. ‡Data missing from database at time of analysis for 22 patients. §Data missing from database at time of analysis for 28 patients.

Table 1: **Baseline characteristics**

Questionnaires were completed in the clinic before interaction with health-care personnel.

Statistical analysis

On the assumption of a 36·7% improvement in median overall survival from 6 months to 8·2 months in patients allocated axitinib plus gemcitabine and non-uniform accrual (roughly 40% of patients enrolled at 7 months), 460 deaths were needed for a log-rank test with an overall one-sided significance level of 0·025 to have a power of 0·90. The assumed improvement in median overall survival was based on results available from the randomised phase 2 trial[6] at the time that this phase 3 study was designed. Applying a 1:1 randomisation, a planned accrual period of 14 months, and a follow-up of roughly 9 months, we estimated that 596 patients would need to enrol to provide 460 deaths. The nominal significance level for the interim futility and efficacy analysis was established with the Pampallona-Tsiatis power boundary and the Lan-DeMets procedure with an O'Brien-Fleming stopping boundary, respectively.[10,11] SAS (version 9.1.3) was used for all analyses.

The primary endpoint of overall survival and other secondary efficacy endpoints were analysed in all patients randomly assigned to treatment groups for whom data were available. Safety and treatment administration and compliance assessments were based on the treatment received. Overall survival was a time-to-event outcome, defined as the time from date of randomisation to date of death from any cause. Objective response rate was defined as the percentage of patients with a confirmed complete or partial response (RECIST). Duration of response was a time-to-event outcome, defined as the time from first documentation of objective tumour response that was subsequently confirmed to first documentation of disease progression or to death from any cause. Time-to-event analyses were done with the Kaplan-Meier method[12] and compared with a one-sided stratified log-rank test at the α=0·025 significance level (the log-rank test was stratified by disease extent [metastatic *vs* locally advanced]); Cox proportional-hazards models were used to explore the effect of baseline characteristics on survival. We compared the proportion of patients with an objective response in each treatment group with a significance level of 0·025 using a one-sided Pearson χ^2 test for unstratified analyses and Cochran-Mantel-Haenszel test for stratified analyses. One-sided significance tests were used because interest centred on whether axitinib plus gemcitabine improved clinical outcomes compared with placebo plus gemcitabine. An interim analysis was planned after roughly half (230) of the deaths had taken place and occurred on Jan 23, 2009.

This study is registered with ClinicalTrials.gov, number NCT00471146.

Role of the funding source

The study was designed by the corresponding author in consultation with the study sponsor. The study sponsor

managed all logistical aspects of the study and collected data. Data analysis was done by the sponsor in collaboration with the global team of academic investigators. All authors had full access to the data, and the corresponding author had final responsibility to submit for publication.

Results

Between July 27, 2007, and Oct 31, 2008, 632 patients were randomly assigned to treatment groups (316 to each group). 305 patients in the gemcitabine plus axitinib group and 308 in the gemcitabine plus placebo group received study treatment (figure 1). The baseline characteristics of the treatment groups seemed well balanced (table 1). Most patients (226 [72%] in the gemcitabine plus axitinib and 227 [72%] in the gemcitabine plus placebo group) had metastatic disease and about half had an ECOG performance status of 1.

The median duration of axitinib treatment was 2·8 months (range 0·03–11·0); the median relative dose intensity (actual total dose/intended total dose) was 100%, with the intended total axitinib dose based on 5 mg twice a day. The median duration of gemcitabine exposure was 2·3 months (range 0·03–11·1) with a median relative dose intensity of 77% in combination with axitinib, versus 2·4 months (0·03–11·8) and 79%, respectively, with placebo. The median number of gemcitabine treatment cycles was three in both groups (range 1–13 for gemcitabine plus axitinib, 1–12 for gemcitabine plus placebo). Dose reductions of axitinib or placebo occurred in 74 (25%) of 298 patients in the axitinib group versus 30 (10%) of 301 patients on the placebo group. Axitinib dose titration to more than 5 mg twice daily occurred in 95 (32%) of 298 patients (range 12–20 mg total daily dose), and 36 (12%) of 298 subsequently needed dose reductions. The dose titrations of axitinib to more than 5 mg twice a day led to a median relative dose intensity of 100%, despite dose reductions occurring in 25% of patients.

At a planned interim analysis in January, 2009, the independent data monitoring committee concluded that the futility boundary had been crossed. Patients on treatment were notified, treatment assignments were unmasked, and discontinuation of axitinib was recommended.

Median follow-up for the gemcitabine plus placebo group was 27 weeks (range 0·1–51·7) and for gemcitabine plus axitinib was 27·4 weeks (0·1–55·5). Median overall survival in the efficacy population was similar in both treatment groups: 8·5 months (95% CI 6·9–9·5) for patients allocated axitinib plus gemcitabine and 8·3 months (6·9–10·3) for those allocated placebo plus gemcitabine (HR 1·014, 95% CI 0·786–1·309; Cox model, one-sided p=0·5436, stratified log-rank test; table 2, figure 2). Median progression-free survival, at 4·4 months, was the same for both treatment groups (HR 1·006, 95% CI 0·779–1·298; one-sided p=0·5203; table 2, figure 2).

Disease stage and ECOG performance status, but not treatment, were strong independent predictors of overall survival (Cox proportional-hazards model; table 3). As expected, patients with locally advanced disease lived longer than did those with metastatic disease, and

	Axitinib plus gemcitabine	Placebo plus gemcitabine	Hazard ratio (95% CI)	One-sided p value
Best response*				
Overall objective response rate	12 (5%, 2·5–8·3)	4 (2%, 0·4–4·0)	..	0·0180
Complete response	1 (<1%)	0	..	..
Partial response	11 (4%)	4 (2%)	..	..
Stable disease	74 (30%)	83 (33%)	..	..
Median survival (months)†				
Overall survival	8·5 (6·9–9·5)	8·3 (6·9–10·3)	1·014 (0·786–1·309)	0·5436
Locally advanced	9·5 (7·4–NR)	10·6 (9·9–NR)	..	..
Metastatic	7·0 (5·8–9·3)	6·9 (6·2–8·0)	..	..
Progression-free survival	4·4 (4·0–5·6)	4·4 (3·7–5·2)	1·006 (0·779–1·298)	0·5203
Locally advanced	5·9 (4·2–7·3)	9·1 (5·8–10·6)	..	..
Metastatic	4·2 (3·7–5·4)	3·8 (3·6–4·5)	..	..

Data for best response are n (%, 95% CI); data for survival are median (95% CI). NR=not reached. *Only patients with measurable disease at baseline were included in the analysis; n=247 for axitinib plus gemcitabine, n=255 for placebo plus gemcitabine. †Analysis included all patients randomly assigned to treatment groups; n=314 for axitinib plus gemcitabine (data missing from database at time of analysis for two patients), n=316 for placebo plus gemcitabine.

Table 2: Efficacy results



Figure 2: Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival

patients with a performance status of 0 lived longer than did those with a status of 1.

502 patients (247 and 255 in the axitinib and placebo groups, respectively) had measurable disease at baseline and could be evaluated for response. The overall objective response rate was 12 (5%) of 247 patients receiving axitinib plus gemcitabine and four (2%) of 255 patients receiving placebo plus gemcitabine (one-sided p=0·0180; table 2). Stable disease was achieved in 74 (30%) of 247 and 83 (33%) of 255 patients in the axitinib and placebo groups, respectively.

Table 4 shows the most common adverse events of any cause, by maximum CTCAE grade. Non-haematological adverse events attributable to VEGF inhibition are presented in table 5. Nausea, diarrhoea, anorexia, dysphonia, hypertension, and stomatitis occurred more frequently in patients receiving axitinib and gemcitabine; peripheral oedema occurred more frequently in patients receiving placebo. Grade 3 or 4 asthenia and hypertension occurred more often in patients on axitinib. Overall, there were two grade 5 events in the placebo group (one cardiac arrest and one cardiac failure) and five in the axitinib group (one each of interstitial lung disease, gastrointestinal haemorrhage, asthenia, acute renal failure, and death).

Grade 3 or 4 deep-vein thrombosis or pulmonary embolism developed in eight (3%) of 305 patients who received axitinib and gemcitabine and 15 (5%) of 308 patients receiving placebo and gemcitabine. Grade 3 or 4 gastrointestinal perforation occurred in four (1%) patients receiving axitinib plus gemcitabine and in two (1%) receiving placebo plus gemcitabine (table 5), mostly associated with tumour involving the bowel wall. Grade 3 or 4 gastrointestinal haemorrhage, probably related to underlying disease, developed in two (1%) patients who received axitinib plus gemcitabine and five (3%) who received placebo plus gemcitabine (table 5).

At study entry, normal concentrations of TSH (<5 μU/mL) were noted in 104 (91%) of 114 patients in the axitinib group and 123 (93%) of 132 patients in the placebo group. Post-treatment increases of TSH (≥5 μU/mL) occurred in 48 (42%) of 114 patients receiving axitinib and gemcitabine and 15 (11%) of 132 patients receiving placebo and gemcitabine, and hypothyroidism as an adverse event was reported in 18 (6%) of 305 patients in the axitinib group and four (1%) of 308 patients taking placebo. 13 of 18 patients who developed hypothyroidism on axitinib plus gemcitabine had asthenia or fatigue, or both, including four grade 3 or 4 cases.

At baseline, the mean scores on the global health status/quality of life scale of the QLQ-C30 did not differ significantly between the two groups (table 1). For patients with a baseline and cycle 4, day 1, value for the global health status scale, after three cycles the mean difference from baseline was 0·1 (n=132) for axitinib plus gemcitabine and 2·8 (n=132) for the placebo group. Patients in the axitinib and gemcitabine group reported a 5-point or more mean change from baseline in pain, constipation, insomnia, and financial difficulties (all improved), and physical functioning, dyspnoea, diarrhoea, and fatigue (all worsened) on the QLQ-C30; on the QLQ-PAN26, patients who received axitinib and gemcitabine reported

	Hazard ratio (95% CI)	p value*
Treatment (axitinib plus gemcitabine *vs* placebo plus gemcitabine)	0·994 (0·770–1·284)	0·9657
Disease stage (locally advanced *vs* metastatic)	0·433 (0·301–0·623)	<0·0001
ECOG performance status (0 *vs* 1)	0·497 (0·380–0·650)	<0·0001

The initial Cox model included baseline factors significant at the 0·10 level in the individual analyses. Backward stepwise selection using an α level of 0·05 was then used to create the final model while forcing treatment to stay in the model/results. ECOG=Eastern Cooperative Oncology Group. *p values are two-sided (Wald χ^2 test).

Table 3: **Multivariate Cox model analysis of overall survival**

	Axitinib plus gemcitabine (n=305)		Placebo plus gemcitabine (n=308)	
	Grade 1 or 2	Grade ≥3	Grade 1 or 2	Grade ≥3
Non-haematological events				
Nausea	129 (42%)*	13 (4%)	106 (34%)	8 (3%)
Fatigue	100 (33%)	27 (9%)	94 (31%)	21 (7%)
Diarrhoea	97 (32%)*	4 (1%)	63 (20%)	5 (2%)
Anorexia	95 (31%)*	19 (6%)	73 (24%)	11 (4%)
Vomiting	86 (28%)	12 (4%)	92 (30%)	10 (3%)
Constipation	85 (28%)	3 (1%)	89 (29%)	7 (2%)
Dysphonia	67 (22%)*	1 (<1%)	13 (4%)	0
Hypertension	65 (21%)*	20 (7%)*	22 (7%)	5 (2%)
Stomatitis	52 (17%)*	0	11 (4%)	1 (<1%)
Pyrexia	47 (15%)	3 (1%)	47 (15%)	1 (<1%)
Abdominal pain	43 (14%)	20 (7%)	41 (13%)	17 (6%)
Peripheral oedema	23 (8%)	0	48 (16%)*	2 (1%)
Haematological abnormalities				
Neutropenia	0	0	3 (1%)	1 (<1%)
Thrombocytopenia	16 (5%)	0	16 (5%)	1 (<1%)
Anaemia	131 (43%)	0	151 (49%)	2 (1%)
Leucopenia	8 (3%)*	0	18 (6%)	0
Lymphopenia	28 (9%)	3 (1%)	42 (14%)	2 (1%)

Data are n (%). *Significant difference in frequency between treatment groups (two-sided 95% CIs exclude 0 for risk differences and 1 for risk ratios).

Table 4: **Adverse events (all causes) reported in 15% or more of patients, and haematological laboratory abnormalities**

	Axitinib plus gemcitabine (n=305)	Placebo plus gemcitabine (n=308)
Asthenia	16 (5%)*†	6 (2%)
Gastrointestinal perforation	4 (1%)	2 (1%)*
Pulmonary embolism	4 (1%)	7 (2%)
Deep-vein thrombosis	4 (1%)	8 (3%)
Gastrointestinal bleeding	2 (1%)	5 (2%)
Cerebrovascular accident	1 (<1%)	1 (<1%)
Proteinuria	1 (<1%)	0

Data are n (%). VEGF=vascular endothelial growth factor. *Includes one grade 5 event. †Significant difference in frequency between treatment groups (two-sided 95% CIs exclude 0 for risk differences and 1 for risk ratios).

Table 5: **Non-haematological grade 3 or 4 adverse events (all causes) attributable to VEGF inhibition or of clinical interest**

improvement in pancreatic pain and worsening in body image, changes in bowel habits, treatment-related side-effects, and ability to plan for the future (data not shown). Patients on placebo reported a 5-point or more mean change from baseline in emotional functioning, pain, constipation, insomnia, and loss of appetite (all improved) on the QLQ-C30; similar changes were seen in pancreatic pain, fear of future health, and cachexia (all improved) on the QLQ-PAN26 (data not shown).

Discussion

This randomised phase 3 trial clearly shows that the addition of axitinib to gemcitabine does not improve survival in patients with locally advanced or metastatic pancreatic cancer. These data also confirm the findings obtained in previous phase 3 studies of the VEGF inhibitors bevacizumab and aflibercept that inhibition of this pathway is ineffective in patients with this disease (panel).[13–15]

In view of the long history of promising phase 2 single-group trials that have yielded negative phase 3 results, some investigators have concluded that a randomised phase 2 trial is the optimum method to predict the benefit of a novel agent in the phase 3 setting.[16] The randomised phase 2 trial design reduces the bias of a comparison with historical data, as well as the patient selection bias. As our study shows, the results of hypothesis-generating, exploratory, randomised, phase 2 studies are not always replicated in randomised phase 3 trials. Indeed, the results of this trial underscore the importance of implementation of phase 3 testing only after a robust signal from appropriately designed phase 2 trials.[17]

The decision to evaluate axitinib in a phase 3 study was based on the results of a fairly small (103 patients), exploratory, randomised, phase 2 study in which gemcitabine plus axitinib showed a non-significant improvement in median overall survival compared with gemcitabine (6·9 months, 95% CI 5·3–10·1 *vs* 5·6 months, 3·9–8·8; HR 0·71, 95% CI 0·44–1·13).[6] That phase 2 study was neither intended nor powered to show a significant difference between the two groups, and the confidence intervals for median overall survival overlapped. Additionally, the confidence interval for the HR contained 1·0. When the decision was made to move forward into phase 3, the HR for overall survival in the phase 2 study was 0·74 in favour of the axitinib plus gemcitabine group. Statistical modelling that took this treatment effect into account, as well as its variability, determined that there was a roughly 65% chance that the phase 3 study would have positive results. We regarded this finding as sufficient justification to undertake this phase 3 trial, although we recognised the significant risk in moving forward from a small phase 2 study to a large phase 3 trial.

The treatment effect in the randomised phase 2 trial was greatest in patients with locally advanced disease and in those with ECOG performance statuses of 0 and 1. The inclusion of 25% of patients with locally advanced disease and almost 50% of patients with performance status 0, plus the exclusion of patients with any thrombosis requiring anticoagulation (who tend to have reduced survival rates), clearly account for the longer-than-anticipated median survival of more than 8 months that was recorded in the control group of this trial. A retrospective analysis from a phase 3 study of gemcitabine and erlotinib plus either bevacizumab or placebo suggests that clinical outcomes might correlate with a genetic locus in the tyrosine kinase domain of VEGF receptor 1.[18] Pharmacogenetic analyses are underway for the present study.

The addition of axitinib to gemcitabine resulted in acceptable tolerability, with a similar incidence of grade 3 or higher adverse events in both groups. Only grade 3 or higher asthenia and hypertension occurred more frequently in patients receiving axitinib than in those allocated placebo. Hypertension was manageable with antihypertensive drugs or axitinib dose reductions, or both. Although venous thrombosis, gastrointestinal bleeding, and gastrointestinal perforations have often been reported with VEGF inhibitors, these were not increased in the axitinib group of this trial.

Analysis of health-related quality of life showed improvements in pancreatic cancer symptoms of pain in both treatment groups. In the axitinib plus gemcitabine group, minor worsening was reported in diarrhoea, fatigue, and changes in bowel habits—side-effects that are typically associated with VEGF inhibition.

Despite the 42% incidence of increased TSH concentration (≥5 μU/mL) in the axitinib plus gemcitabine group, only 6% of patients were diagnosed with hypothyroidism and received hormone replacement therapy. Whether any patients with TSH increase had subclinical hypothyroidism,

Panel: Research in context

Systematic review

Although a systematic review was not done as part of the planning for this trial, the existing evidence in this area was identified by literature (Medline) searches. Medline search terms included "pancreatic cancer", "chemotherapy", "gemcitabine"; search limited to English language, 1997–2007. Previous key trials of gemcitabine-based regimens in pancreatic adenocarcinoma have shown poor outcomes and low survival rates. An exploratory randomised phase 2 trial[6] showed that the combination of gemcitabine and axitinib in this setting resulted in a numerical improvement in median overall survival compared with gemcitabine alone. The rationale for the present phase 3 trial of axitinib plus gemcitabine was to further investigate and to confirm findings from the phase 2 study.

Interpretation

Results from this trial show that the addition of axitinib to gemcitabine does not improve survival for patients with advanced pancreatic cancer. The data thus add to increasing evidence that targeting of vascular endothelial growth factor (VEGF) signalling is an ineffective strategy in advanced pancreatic cancer. This conclusion is supported by results of phase 3 trials showing that addition of other VEGF inhibitors such as bevacizumab or aflibercept to gemcitabine did not improve survival compared with gemcitabine plus placebo in patients with advanced pancreatic cancer. On the basis of data from this trial, we recommend that no changes to treatment paradigms for advanced pancreatic cancer are indicated.

or whether hormone replacement therapy would have been beneficial, is uncertain.

In conclusion, the addition of axitinib to gemcitabine does not improve survival for patients with advanced pancreatic cancer. These results add to increasing evidence that targeting of VEGF signalling is an ineffective strategy in this disease.

Contributors

HLK contributed to study design, data collection, analysis, and interpretation, literature search, and writing of the report. TI contributed to data collection and interpretation and review of the report. DJR contributed to patient inclusion, data interpretation, and writing and review of the report. JB contributed to inclusion of patients in the study and writing of the report. RL contributed to recruitment and follow-up of patients and review of the report. TO contributed to recruitment and management of patients, data collection, and review of the report. AF contributed to data collection and interpretation and review of the report. JF contributed to study design, data collection and interpretation, and review of the report. YSP contributed to data collection and interpretation and writing and review of the report. SO contributed to data collection and interpretation and review of the report. GMS contributed to data collection and writing of the report. HSW provided study design advice and contributed to recruitment of study participants, UK ethics submission, and report review and contribution. PCT contributed to study design, data analysis and interpretation, and writing of the report. PB contributed to study design, data collection and analysis, data interpretation, and writing of the report. ADR contributed to study design, data collection, analysis, and interpretation, and writing of the report. SK contributed to design, writing of the protocol, data analysis and interpretation, and editing of the report. EVC contributed to data collection, analysis, and interpretation and writing of the report. All authors provided final approval of the report.

Conflicts of interest

Pfizer provided TI with a flight ticket and accommodation for attending an investigator meeting for the reported study (the meeting was sponsored by Pfizer); Pfizer paid TI's institution the necessary cost to conduct the study. JB has received compensation for board membership from Roche, Bayer, and Boehringer; and payment for lectures, including service on speakers' bureaus from Roche and AstraZeneca. RL's institution received a fee per patient from Pfizer for participation in the study (research nurse work, etc). TO's institution has received research funding from Pfizer in relation to the work under consideration for publication; it has also received research funding unrelated to the submitted work from Eli Lilly, Taiho, Dainippon-Sumitomo, Bayer, Chugai, Otsuka, Novartis, Kowa, Pfizer, Yakult, Eisai, Oncotherapy Science, Bristol-Myers Squibb, Abbott, Takeda Bio, and Nippon Kayaku. TO received travel expenses for the study from Pfizer; he has also received payment for lectures unrelated to the submitted work from Taiho, Eli Lilly, Asuka, Bayer, Chugai, Novartis, Torii, Nippon Kayaku, Pfizer, Janssen, AstraZeneca, Dainippon-Sumitomo, Wyeth, and Ajinomoto. Pfizer provided AF with a flight ticket and accommodation for attending an investigator meeting for the reported study (the meeting was sponsored by Pfizer); Pfizer paid AF's institution the necessary cost to conduct the study. JF has received payment for lectures, including service on speakers' bureaus from Bayer, Taiho, Eli Lilly, and Eisai; Pfizer paid JF's institution the necessary cost to conduct the study. Pfizer paid SO's institution the necessary cost to conduct the study; SO's institution has received research funding from Eli Lilly, Taiho, Chugai, Yakult, Oncotherapy Science, Abbott, and Dainippon-Sumitomo. SO has received payment for lectures from Eli Lilly, Taiho, Kyowa Hakko Kirin, and Hisamitsu. GMS's institution has received a grant from Pfizer in relation to the work under consideration for publication. HSW's institution received money from Pfizer for running the trial and per patient payments to cover trial costs; HSW has received compensation from Pfizer for participation in two advisory boards during the past year (clinical trial and scientific development programmes by Pfizer). EVC's institution received a grant from Pfizer in relation to the work under consideration for publication; and it also has grants or grants pending from Pfizer outside of the submitted work. PCT, PB, ADR, and SK are compensated as employees of Pfizer and own stock or stock options in Pfizer. HLK, DJR, and YSP declare that they have no conflicts of interest.

Acknowledgments

We thank the participating patients and their families, as well as the investigators, research nurses, study coordinators, and operations staff. This study was sponsored by Pfizer. Medical writing support provided by Molly Heitz (Acumed, Tytherington, UK) and manuscript submission support provided by Larry Rosenberg (UBC Scientific Solutions, Southport, CT, USA) was funded by Pfizer.

References

1 Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin* 2010; **60:** 277–300.

2 Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; **15:** 2403–13.

3 Van Cutsem E, Verslype C, Grusenmeyer PA. Lessons learned in the management of advanced pancreatic cancer. *J Clin Oncol* 2007; **25:** 1949–52.

4 Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007; **25:** 1960–66.

5 Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. *Clin Cancer Res* 2008; **14:** 7272–83.

6 Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. *Lancet* 2008; **371:** 2101–08.

7 Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000; **92:** 205–16.

8 Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993; **85:** 365–76.

9 Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. *Eur J Cancer* 1999; **35:** 939–41.

10 Pampallona S, Tsiatis AA. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. *J Stat Plan Infect* 1994; **42:** 19–35.

11 Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. *Biometrika* 1983; **70:** 659–63.

12 Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958; **53:** 457–81.

13 Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). *J Clin Oncol* 2010; **28:** 3617–22.

14 Sanofi-Aventis, Regeneron Pharmaceuticals Inc. Phase 3 trial of aflibercept in metastatic pancreatic cancer discontinued. 2009. http://en.sanofi-aventis.com/binaries/20090911_aflibercept_en_tcm28-26185.pdf (accessed Oct 19, 2009).

15 Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *J Clin Oncol* 2009; **27:** 2231–37.

16 Cannistra SA. Phase II trials in the Journal of Clinical Oncology. *J Clin Oncol* 2009; **27:** 3073–76.

17 Philip PA, Mooney M, Jaffe D, et al. Consensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatment. *J Clin Oncol* 2009; **27:** 5660–69.

18 Lambrechts D, Delmar P, Buysschaert I, et al. VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer. *Eur J Cancer Suppl* 2009; **7:** 10 (abstr).

Cancer Science
The official journal of the Japanese Cancer Association JCA

Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer

Takuji Okusaka,[1,14] Junji Furuse,[2,3] Akihiro Funakoshi,[4] Tatsuya Ioka,[5] Kenji Yamao,[6] Shinichi Ohkawa,[7] Narikazu Boku,[8] Yoshito Komatsu,[9] Shoji Nakamori,[10] Haruo Iguchi,[11] Tetsuhide Ito,[12] Kazuhiko Nakagawa[13] and Kohei Nakachi[2]

[1]National Cancer Center Hospital, Tokyo; [2]National Cancer Center Hospital East, Kashiwa; [3]Kyorin University School of Medicine, Tokyo; [4]National Kyushu Cancer Center, Fukuoka; [5]Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka; [6]Aichi Cancer Center Hospital, Nagoya; [7]Kanagawa Cancer Center Hospital, Yokohama; [8]Shizuoka Cancer Center, Shizuoka; [9]Hokkaido University Hospital, Sapporo; [10]National Hospital Organization Osaka National Hospital, Osaka; [11]National Hospital Organization Shikoku Cancer Center, Ehime; [12]Kyushu University, Fukuoka; [13]Kinki University School of Medicine, Osaka, Japan

(Received April 1, 2010/Revised October 16, 2010/Accepted November 11, 2010/Accepted manuscript online November 26, 2010/Article first published online December 22, 2010)

Erlotinib combined with gemcitabine has not been evaluated in Japanese patients with unresectable pancreatic cancer. This two-step phase II study assessed the safety and pharmacokinetics of erlotinib 100 mg/day (oral) plus gemcitabine 1000 mg/m^2 (i.v. days 1, 8, 15) in a 28-day cycle in the first step, and efficacy and safety in the second step. The primary end-point was safety. One hundred and seven patients were enrolled (first step, n = 6; second step, n = 101). The most common adverse event was RASH (compiled using the preferred terms rash, acne, exfoliative rash, dermatitis acneiform, erythema, eczema, dermatitis and pustular rash) in 93.4% of patients. One treatment-related death occurred. While interstitial lung disease-like events were reported in nine patients (8.5%; grade 1/2/3, 3.8/2.8/1.9%), all patients recovered or improved. The median overall survival, the 1-year survival rate and median progression-free survival were 9.23 months, 33.0% and 3.48 months, respectively. The overall response and disease control rates were 20.3% and 50.0%, respectively. In Japanese patients with unresectable pancreatic cancer, erlotinib plus gemcitabine had acceptable toxicity and efficacy that was not inferior to that seen in Western patients. (*Cancer Sci* 2011; 102: 425–431)

Approximately 232 000 individuals are diagnosed with pancreatic cancer worldwide each year, with an annual death rate estimated at 227 000.[1] In Japan, approximately 22 000 new cases were reported in 2005.[2] Furthermore, data from 2007 show that around 24 000 individuals in Japan died from pancreatic cancer, making this tumor type the fifth leading cause of cancer-related death.[3] The majority of pancreatic cancer cases are diagnosed at an unresectable stage when prognosis is extremely poor.

Current treatment for advanced pancreatic cancer is based on systemic chemotherapy with gemcitabine. Single-agent gemcitabine has been shown to extend median overall survival (OS) to 5.65 months in chemonaïve patients compared with 4.41 months in patients who received fluorouracil.[4] Addition of other cytotoxic agents to gemcitabine has not demonstrated survival benefits over gemcitabine alone.[5–13] The potential of combining gemcitabine with biological agents in patients with advanced pancreatic cancer has also been evaluated in several phase III studies, but these trials failed to show a survival benefit.[14–19]

Epidermal growth factor receptor (EGFR)-mediated signaling is associated with various cellular processes, and the dysregulation of these processes is common in tumorigenesis.[20,21] Furthermore, EGFR is overexpressed in many tumors and its overexpression is often associated with poor prognosis.[22–26] EGFR tyrosine-kinase inhibitors (TKI, such as erlotinib) are used in the treatment of various types of solid tumors.

Erlotinib has demonstrated antitumor activity in pancreatic cell lines[27] and was subsequently assessed as a potential therapeutic agent in pancreatic cancer. In the PA.3 study (n = 569), the risk of death with erlotinib plus gemcitabine was reduced by 18% versus gemcitabine alone (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.69–0.99; P = 0.038 after adjustment for stratification factors), with a median OS of 6.24 months *vs* 5.91 months, respectively. Erlotinib plus gemcitabine combination therapy provided significant improvements in the 1-year survival rate (23% *vs* 17%; P = 0.023) and progression-free survival (PFS; HR 0.77; 95% CI, 0.64–0.92; P = 0.004).[28] As a result, this combination was approved for use in pancreatic cancer in many countries.

In Japanese patients with non-small-cell lung cancer (NSCLC), a phase II study has specifically shown that erlotinib monotherapy is well tolerated and has promising antitumor activity.[29] However, there are no data on the use of erlotinib combined with gemcitabine in Japanese patients with pancreatic cancer. This phase II study evaluated the safety and efficacy of erlotinib in combination with gemcitabine in Japanese patients with unresectable locally advanced or metastatic pancreatic cancer.

Methods

Patients. Patients aged 20–80 years with histological/cytological evidence of unresectable locally advanced or metastatic adenocarcinoma/adenosquamous carcinoma of the pancreas were eligible for inclusion in the present study. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2, adequate hematological, renal and hepatic function and a life expectancy of at least 2 months. No more than one prior regimen for pancreatic cancer was permitted. Patients who had received prior gemcitabine and/or a TKI were excluded from participation, as were those who had previously been exposed to a human epidermal growth factor receptor 2 (HER2) or EGFR inhibitor. Other key

[14]To whom correspondence should be addressed.
E-mail: tokusaka@ncc.go.jp
Clinical trial registry: JAPIC Clinical Trials Information (see links below). http://rctportal.niph.go.jp/examDetail.php?center=3&center_seq=698 http://www.clinicaltrials.jp/user/cteDetail.jsp?clinicalTrialId=839&language=ja. Trial registration number: JapicCTI-060337.

doi: 10.1111/j.1349-7006.2010.01810.x

exclusion criteria were: symptomatic cerebral metastases; a concurrent lung disorder (such as idiopathic pulmonary fibrosis, interstitial lung disease [ILD] or pneumoconiosis); concurrent or previous drug-induced pneumonia; or a history of radiation to the chest.

The study complied with the Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was obtained from all patients, and the protocol was approved by ethics committees at all participating institutions.

Study design and treatment. This was a phase II, multicentre, open-label, two-step study. In the first step, six patients were enrolled into the study and treated with oral erlotinib 100 mg/day on days 3–28, plus i.v. gemcitabine 1000 mg/m^2 on days 1, 8 and 15 in a 28-day cycle. The starting doses of erlotinib and gemcitabine were chosen in reference to the PA.3 study. Dose-limiting toxicities (DLT) were assessed in these study participants using the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (NCI-CTCAE, National Cancer Institute, Bethesda, MD, USA). Dose-limiting toxicities were defined in conformity to the P1b study as follows:[30] (i) grade 4 decrease (i.e. to <500/mm^3) in neutrophil count >5 days; (ii) grade ≥3 decrease (i.e. to <1000/mm^3) in neutrophil count with associated fever (≥38.5°C); (iii) grade 4 decrease in platelet count (i.e. to <25 000/mm^3); (iv) any grade ILD; (v) grade 4 elevation of alanine transaminase (ALT)/aspartate transaminase (AST) levels, or grade 3 elevation of ALT/AST levels >7 days; (vi) grade ≥3 non-hematological toxicity (excluding rash, hyperglycemia, γ-GTP and events that were judged to be transient/had no effect on study continuation); and (vii) dose-reduction/interruption required due to persistent adverse events (AE), which meant that the second cycle could not be started.

If treatment-related DLT occurred in no more than two of the six patients, transition to the second step of the study was permissible with approval of the Data Safety and Monitoring Committee (DSMC). If DLT occurred in three or more patients, transition to the second step was limited to those cases that were judged to be safe for this study after the DSMC had evaluated the safety data of the patients with a DLT. In the second step, it was planned that 94 patients would be treated with the same dose as the first step. Treatment was continued until disease progression, death, unacceptable toxicity or patient/investigator request.

The primary end-point of the study was safety, with secondary end-points including OS, 1-year survival rate, PFS, overall response rate (ORR), disease control rate (DCR = complete response [CR] + partial response [PR] + stable disease), pharmacokinetics (PK) and correlation of *EGFR* mutation status with outcomes.

Toxicity evaluation. Adverse events were monitored and graded using NCI-CTCAE v3.0. Clinical and laboratory assessments were conducted throughout the study. Adverse events prespecified in the study to be monitored carefully were rash, diarrhea, vomiting, liver dysfunction and ILD-like events. Chest X-ray examination to assess pulmonary toxicity was conducted weekly until week 4 and every 2 weeks thereafter. In addition, chest computed tomography (CT) scan was performed every 4 weeks. The DSMC reviewed the images and clinical data associated with all potential ILD-like events. All ILD-like events were reported to be serious AE (SAE), regardless of the grade.

Efficacy evaluation. The tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) in patients who had at least one measurable target lesion. Tumors were measured using computed tomography (CT) at baseline and on day 22 of every two cycles thereafter. Median PFS, ORR and DCR were estimated by the extramural review. The relationship between efficacy and the severity of RASH (compiled using the preferred terms rash, acne, exfoliative rash, dermatitis acneiform, erythema, eczema, dermatitis and pustular rash) was also examined.

Pharmacokinetic evaluation. Pharmacokinetic evaluation of erlotinib and its O-desmethylated metabolite (OSI-420) was performed in the six patients enrolled in the first step of the study. Venous blood samples were taken prior to erlotinib dosing on day 3 and day 8 of cycle 1 at 0.5, 1, 2, 4, 6, 8 and 24 h after erlotinib administration. Samples were also taken prior to gemcitabine infusion on days 1 and 8 at 0.5, 0.75, 1, 1.5, 2.5 and 4.5 h after dosing.

The plasma concentrations of erlotinib, OSI-420 and gemcitabine were measured by liquid chromatography, tandem mass spectrometry (LC-MS-MS). The LC-MS-MS analytical methods have been described previously.[31,32] Derived PK parameters included the maximum plasma drug concentration (C_{max}), time to C_{max} (t_{max}), area under the plasma drug concentration-time curve to the last plasma sample (AUC_{last}), terminal half-life ($t_{½}$) and oral clearance (Cl/F).

Biomarker analysis. *EGFR* mutations were assessed in patients with available tumor tissue specimens, which were formalin fixed and paraffin embedded. Samples were analyzed at a central laboratory where DNA was extracted and exons 18–21 sequenced using a nested PCR.

Statistical analysis. Progression-free survival and OS were estimated using the Kaplan–Meier method in all patients who received at least one dose of the study treatment, with 95% CI for the median duration calculated using Greenwood's formula. The Clopper–Pearson method was used to calculate the 95% CI around the ORR, DCR and AE rate. Multivariate analyses were performed for the occurrence of ILD-like events using the logistic regression model. Baseline characteristics investigated for this analysis included gender, age, lung metastasis, emphysema and various baseline laboratory values. The target enrollment was 100 patients, as this was required to evaluate the safety of erlotinib.

Results

Patient characteristics. Between December 2006 and October 2007, a total of 107 patients were enrolled (first step, n = 6; second step, n = 101) from 12 institutions (Fig. 1). One patient who enrolled into the second step did not receive treatment due to deterioration in PS prior to the start of treatment. A total of 106 patients were evaluable for safety (safety population, full analysis set).

The patient demographics and baseline characteristics are shown in Table 1. The median age was 62 years (range, 36–78) and 52.8% of patients were male. Almost all patients were chemonaïve (95.3%). The majority (75.5%) of patients had an ECOG PS of 0 and most (83.0%) had metastatic disease. Over half (63.2%) of the patients had a history of current or past smoking.

Toxicity and dose modifications. The median duration of erlotinib exposure was 102.5 days and its median dose intensity was 100.0 mg/day, with the majority of patients (78.3%) receiving more than 90% of the relative dose intensity. The median duration of gemcitabine treatment was 4.0 cycles and its median dose intensity was 688.0 mg/m^2 per week, with approximately half of the patients (51.4%) receiving more than 90% of the relative dose intensity.

As only one patient had a DLT (grade 3 diarrhea) in the first step, the second step of the study was initiated. One hundred and six patients received at least one dose of erlotinib; these patients were assessable for toxicity. Treatment-related AE and treatment-related changes in laboratory values are summarized in Table 2; most of these were mild to moderate in severity. The most frequently reported AE was RASH, which occurred in

doi: 10.1111/j.1349-7006.2010.01810.x



Fig. 1. Kaplan–Meier estimates of (A) overall survival (OS) and (B) progression-free survival (PFS) in the study population (n = 106); (C) OS and (D) PFS according to the severity of RASH (grade ≤1 [n = 39] *vs* grade ≥2 [n = 67]). RASH is a composite of the terms: rash, acne, exfoliative rash, dermatitis acneiform, erythema, eczema, dermatitis and pustular rash. CI, confidence interval.

Table 1. Baseline characteristics and demographics (n = 106)

Characteristic	
Median age (range) (years)	62 (36–78)
Gender, n (%)	
Male	56 (52.8)
Female	50 (47.2)
Median bodyweight (range) (kg)	52.3 (33.1–95.0)
Smoking history,† n (%)	
Never smoker	39 (36.8)
Past smoker	37 (34.9)
Current smoker	30 (28.3)
ECOG PS, n (%)	
0	80 (75.5)
1	26 (24.5)
2	0 (0)
Disease status, n (%)	
Metastatic	88 (83.0)
Locally advanced	18 (17.0)
Primary tumor identified, n (%)	92 (86.8)
Primary sites, n (%)	
Head	46 (43.4)
Body and tail	23 (21.7)
Body	22 (20.8)
Tail	10 (9.4)
Other	5 (4.7)‡
Biliary drainage, n (%)	19 (17.9)
Sites of distant metastases, n (%)	
Liver	56 (52.8)
Distant lymph nodes	39 (36.8)
Lung	17 (16.0)
Other	26 (24.5)
Prior lines of therapy, n (%)	
None	101 (95.3)
One regimen	5 (4.7)§
Median CA19–9 (range) (U/mL)	
Median	776 (0–435 000)
Median CEA (range) (ng/mL)	
Median	4.8 (0.6–1100.1)

†Never smoker, never/hardly smoked; past smoker, passage of at least 1 month since stopping smoking (at the time of registration); current smoker, smoked within 1 month (at the time of registration). ‡Whole of pancreas (n = 1); head and body (n = 3); other (n = 1). §Tegafur, gimeracil, oteracil potassium (S-1) (n = 3); 5-fluorouracil plus leucovorin (n = 2). CA 19–9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; ECOG, Eastern Co-Operative Group.

93.4% of the patients; most cases were mild to moderate in severity (87.7%, grade ≤2; 5.7%, grade ≥3). Other common non-hematological AE included anorexia, pruritus, fatigue, nausea and diarrhea. Most patients experienced some degree of hematological toxicity, with grade 3 or 4 neutropenia (neutrophil decreased), leucopenia (white blood cell count decreased) and anemia (hemoglobin decreased) occurring in 34.9%, 29.2% and 14.2% of patients, respectively. Only one treatment-related death occurred (due to gastrointestinal hemorrhage), which was probably due to arterial bleeding caused by the invasion of the primary tumor into the gastrointestinal tract. Although the likelihood of this event being treatment-related was deemed remote, a causal relationship could not be completely excluded because the event occurred during the study treatment administration period.

Treatment-related SAE were reported in 26 (24.5%) patients. These included nine ILD-like events (8.5%), the majority of which (n = 7) were grade 1–2 in severity. Importantly, all of these nine patients recovered or improved, and four of these patients did so without any treatment for ILD-like events. Other

Table 2. Treatment-related adverse events occurring in >30% of patients treated with erlotinib and gemcitabine (n = 106)

	Any grade, n (%)	Grade 3, n (%)	Grade 4, n (%)
Non-hematological			
Rash	78 (73.6)	3 (2.8)	0 (0)
Anorexia	75 (70.8)	15 (14.2)	0 (0)
Pruritus	57 (53.8)	1 (0.9)	0 (0)
Fatigue	56 (52.8)	3 (2.8)	0 (0)
Nausea	56 (52.8)	6 (5.7)	0 (0)
Diarrhea	52 (49.1)	2 (1.9)	0 (0)
Dry skin	49 (46.2)	0 (0)	0 (0)
Stomatitis	38 (35.8)	0 (0)	0 (0)
Pyrexia	32 (30.2)	0 (0)	0 (0)
Hematological			
White blood cell count decreased	85 (80.2)	31 (29.2)	0 (0)
Platelet count decreased	77 (72.6)	9 (8.5)	0 (0)
Hemoglobin decreased	76 (71.7)	13 (12.3)	2 (1.9)
Hematocrit decreased	73 (68.9)	8 (7.5)	0 (0)
Neutrophil decreased	73 (68.9)	32 (30.2)	5 (4.7)
Red blood cell count decreased	72 (67.9)	8 (7.5)	0 (0)
ALT increased	59 (55.7)	10 (9.4)	0 (0)
AST increased	57 (53.8)	4 (3.8)	1 (0.9)
Weight decreased	53 (50.0)	3 (2.8)	0 (0)
Lymphocyte count decreased	46 (43.4)	14 (13.2)	0 (0)
Blood albumin decreased	35 (33.0)	0 (0)	0 (0)
Gamma-glutamyltransferase increased	35 (33.0)	12 (11.3)	1 (0.9)

ALT, alanine amino transferase; AST, aspartate amino transferase.

treatment-related SAE were anorexia (3.8%), vomiting, pyrexia and abnormal hepatic function (1.9% each). The baseline characteristics, treatment and outcomes of patients who developed treatment-related ILD-like events during the study are detailed in Table 3. The onset times of ILD-like events ranged from 7 to 187 days after the start of treatment. In these patients, a relatively long survival was observed (from 119 to 568+ days), and five patients received post-study therapy. All of these nine patients were past or current smokers, and six had emphysema at baseline (not detected prior to treatment, but diagnosed at the extramural review by a radiologist in the DSMC). Multivariate analyses were performed for the occurrence of ILD-like events using the logistic regression model and emphysema at baseline was indicated as a risk factor for onset of ILD-like events (odds ratio [95% CI], 12.13 [1.01–145.7]; P = 0.0491).

Adverse events led to erlotinib discontinuation in 30 patients (28.3%) and gemcitabine discontinuation in 27 patients (25.5%). The main reasons for treatment discontinuation were ILD (n = 6) and anorexia (n = 3); no patient discontinued treatment due to RASH or diarrhea. Due to the onset of AE, a total of 65 patients (61.3%) required one or more interruptions of erlotinib (36 patients [34.0%] for longer than seven consecutive days and 17 patients [16.0%] for longer than 14 consecutive days) and 56 patients (52.8%) had one or more skip of gemcitabine. Modifications in the erlotinib or gemcitabine dosage were required in 17 (16.0%) and 11 (10.4%) patients, respectively, due to AE.

Efficacy. The median OS was 9.23 months (95% CI, 8.31–10.78; Fig. 1A) and the 1-year survival rate was 33% (95% CI, 24–42). Median PFS was 3.48 months (95% CI, 2.63–3.78; Fig. 1B). Among the patients evaluable for tumor response (n = 64), the ORR was 20.3% (13/64; 95% CI, 11.3–32.2) and the DCR was 50.0% (95% CI, 37.2–62.8; CR, n = 0; PR, n = 13; stable disease, n = 19).

doi: 10.1111/j.1349-7006.2010.01810.x

Table 3. Characteristics, treatment and outcomes of patients with treatment-related ILD-like events (n = 9)

Event	Gender	Age (years)	Smoking status†	Days on treatment	ILD maximum grade	Suspicious findings of ILD	Steroids	Oxygen	ILD outcome	Presence of emphysema (assessed by radiologist)	Survival outcome (days)	Post-therapy (chemotherapy)
Lymphoid ILD	M	62	Past	82	1	Pyrexia	None	No	Improved	Yes	362	Yes
ILD	M	42	Current	50	3	Pyrexia	Pulse	Yes	Recovered	Yes	517	Yes
Organising pneumonia	M	60	Past	183	2	Respiratory symptoms	None	No	Improved	Yes	568+	Yes
ILD	F	62	Past	113	2	Cough	Oral	No	Recovered	Yes	376	No
ILD	F	74	Past	111	3	Cough, dyspnea	Pulse	Yes	Improved	None	183	No
ILD	M	60	Current	25	1	Pyrexia	Pulse	No	Recovered	None	119	Yes
ILD	M	77	Past	7	1	X-ray	None	No	Recovered	Yes	255	No
ILD	M	55	Past	187	1	CT	None	No	Recovered	Yes	415	No
ILD	F	60	Current	76	2	Cough	Oral	No	Recovered	None	346	Yes

†Past smoker, passage of at least 1 month since stopping smoking (at the time of registration); current smoker, smoked within 1 month (at the time of registration). CT, computed tomography; F, female; ILD, interstitial lung disease; M, male.

The median OS was longer in patients who experienced RASH of grade ≥2 (n = 67) than in those with RASH of grade ≤1 (n = 39) (10.25 months [95% CI, 8.80–12.12] *vs* 8.31 months [95% CI, 6.18–9.99], respectively; Fig. 1C) and the 1-year survival rate was higher (39% [95% CI, 27–50] *vs* 23% [95% CI, 10–36], respectively). Similarly, the median PFS was longer in patients with RASH of grade ≥2 versus those with RASH grade ≤1 (3.61 months [95% CI, 3.48–5.32] *vs* 1.81 months [95% CI, 1.64–3.48]; Fig. 1D). While there was no notable difference in ORR between patients with RASH grade ≥2 and those with grade ≤1 (21.1% [95% CI, 9.6–37.3] *vs* 19.2% [95% CI, 6.6–39.4]), the DCR was higher in those with more severe RASH (60.5% [95% CI, 43.4–76.0] *vs* 34.6% [95% CI, 17.2–55.7]).

Pharmacokinetics. Plasma sampling for PK analyses was performed in all six patients enrolled in the first step. On day 8, the values of C_{max} were 1760 ± 456.9 ng/mL (mean ± SD) for erlotinib, 169.7 ± 64.5 ng/mL for OSI-420 and 22 700 ± 3272.9 ng/mL for gemcitabine. The AUC_{last} was 29 001 ± 6560 h ng/mL, 2748 ± 788 h ng/mL and 10 717 ± 1458 h ng/mL (mean ± SD), respectively. The mean t_{max} was 8.0 h (range, 2.0–23.9 h), 9.0 h (2.0–23.9 h) and 0.51 h (0.45–0.57 h), respectively. Also on day 8, the mean plasma $t_{1/2}$ was 54.92 h (range, 9.25–144.61 h), 32.79 h (10.36–60.46 h), and 0.63 h (0.31–1.14 h), respectively. The Cl/F of erlotinib and gemcitabine showed interindividual variability; the Cl/F on day 8 was 3972.6 ± 772.1 mL/h (mean ± SD; coefficient of variation 19.4%) and 146 580.4 ± 31 101.3 mL/h (21.2%), respectively.

Biomarker analysis. Of the 106 patients enrolled, *EGFR* mutation status was evaluated in 47 patients (44.3%), all of whom had wild-type *EGFR*. The mutation status of the remaining patients was classified as unknown because samples were not available (30.2%), not examined (9.4%) or the results following sequencing were inconclusive (16.0%).

Discussion

This study was designed to initially assess the safety of erlotinib with gemcitabine for Japanese patients with pancreatic cancer, in whom there had been no prior exposure to either drug. As no significant safety concerns were raised in the first step of the study, enrollment of a further 101 patients was performed. Although the incidence of AE in this study was higher than in the PA.3 study, the incidence of grade 3–4 AE was similar.[28] Despite these results, no new AE specific to Japanese patients were observed. As expected, RASH and gastrointestinal events were among the most common AE in this study, and most of these cases were mild to moderate in severity.

Interstitial lung disease-like events were reported in nine patients (8.5%; grade 1/2/3, 3.8/2.8/1.9%) in the current study, while its incidence was reported to be 2.4% in patients treated in the erlotinib plus gemcitabine arm of the PA.3 study.[28] In addition, in Japanese patients with advanced pancreatic cancer, ILD-like events were reported in two (6.1%) of 33 patients treated with gemcitabine plus S-1, and were reported in three (1.1%) of 264 patients with gemcitabine monotherapy, respectively.[33,34] Likewise, the higher incidence of ILD-like events were documented using S-1 or erlotinib in combination with gemcitabine compared with gemcitabine as monotherapy in patients with pancreatic and biliary tract cancer.[35] On another front, outside of Japan, a high incidence of ILD-like events was reported in gemcitabine and paclitaxel combination therapy in patients with NSCLC.[36] From the above information, considering the higher incidence of ILD when gemcitabine is used in combination, an additive effect from such combinations cannot be ruled out.

In NSCLC, Japanese patients have an increased risk of developing ILD-like events when treated with EGFR TKI.[29,37–39] Fatal cases of ILD-like events have been reported following EGFR TKI administration for the treatment of NSCLC.[37–41] Importantly, however, no patients died due to an ILD-like event in this study. Seven patients experienced ILD-like events of grade 1–2 in severity. This may be due to active management of ILD-like cases during the study period. This management included regular and immediate chest X-rays, in addition to diagnosis with CT scans after any early signs and symptoms were observed (e.g. pyrexia, cough or dyspnea), timely discontinuation of the antitumor drugs (as a precautionary measure in case these drugs were associated with the symptoms) and appropriate treatment for the events (including oral/pulse steroids). By appropriately treating the early symptoms of ILD-like events, patients could restart antitumor therapy (chemotherapy: treatment change). In this study, the onset time for ILD-like events varied markedly between patients (7–187 days). It is therefore necessary to monitor the patients throughout the treatment period.

All of the patients who developed ILD in this study were current or past smokers, and smoking status has been shown to be a risk factor for ILD in the NSCLC population.[38] Results from the multivariate analyses in this study suggest that emphysema is also a risk factor for developing ILD; six of the nine

patients with ILD-like events were diagnosed with emphysema at baseline. Although the number of reports of an ILD-like event may have been artificially elevated due to underlying patient baseline characteristics and the active management of ILD-like events, these results demonstrate the need to consider the risk of ILD-like events in Japanese patients treated with TKI. In particular, it is important that chest CT scans are closely checked for the presence of emphysema or comorbid ILD and that pulmonary status is assessed prior to treatment administration.

This study corroborates the results of the combination of gemcitabine and erlotinib shown in the PA.3 study. The median OS in this study of 9.23 months was longer than those reported in trials with gemcitabine alone. In this study, patients who experienced skin toxicity of grade ≥2 had better outcomes than those with less severe toxicity or the overall study population. Retrospective analyses of data from the PA.3 and AViTA studies have found a significant association between the development of skin toxicity and efficacy in patients with pancreatic cancer treated with erlotinib-based therapy, although the precise mechanisms for the association between skin toxicity and effectiveness are unknown.[28,41,42]

Although the presence of mutations in the tyrosine-kinase region of the *EGFR* gene appears to predict a better response to erlotinib in NSCLC,[43,44] this has not yet been evaluated in pancreatic cancer. *EGFR* mutations are very rare in patients with pancreatic cancer;[45–47] indeed in the present study, no *EGFR* mutations were detected. Further work is required to determine whether *EGFR* mutations can be used as predictive markers for improved survival in Japanese patients receiving erlotinib and gemcitabine as treatment for advanced pancreatic cancer.

In conclusion, the present study shows that erlotinib in combination with gemcitabine is generally well tolerated in Japanese patients with advanced pancreatic cancer. This combination is associated with efficacy and survival outcomes, and the results of this study are consistent with the findings of the global PA.3 study.

Acknowledgments

The authors would like to thank all the patients, investigators and site staff involved in the study. We are grateful to Masahiro Fukuoka for acting as a medical advisor for this study. The authors also thank Abdul Al Khateeb of Gardiner–Caldwell Communications for editorial assistance. This study was sponsored by Chugai Pharmaceutical Co., Ltd. Editorial assistance from Abdul Al Khateeb of Gardiner–Caldwell Communications was funded by Chugai Pharmaceutical Co., Ltd.

Disclosure Statement

Junji Furuse received honoraria for lecture fees from Bayer, Eli Lilly Japan, Taiho Pharmaceutical and Eisai; Kazuhiko Nakagawa received honoraria for lecture fees from Eli Lilly Japan, Chugai Pharmaceutical and AstraZeneca; Takuji Okusaka, Akihiro Funakoshi, Tatsuya Ioka, Kenji Yamao, Shinichi Ohkawa, Narikazu Boku, Yoshito Komatsu, Shoji Nakamori, Haruo Iguchi, Tetsuhide Ito and Kohei Nakachi have no conflict of interest.

References

1 Parkin DM, Bray F, Ferlay J *et al.* Global cancer statistics, 2002. *CA Cancer J Clin* 2005; **55**: 74–108.
2 Japanese Ministry of Health, Labour and Welfare. Statistical investigation result 2005. (In Japanese.) [Cited 16 Feb 2010.] Available from URL: http://www-bm.mhlw.go.jp/toukei/saikin/hw/kanja/05syoubyo/index.html.
3 Japanese Ministry of Health, Labour and Welfare. Table database system. (In Japanese.) [Cited 16 Feb 2010.] Available from URL: http://www.mhlw.go.jp/toukei/youran/indexyk_1_2.html.
4 Burris HA III, Moore MJ, Andersen J *et al.* Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; **15**: 2403–13.
5 Berlin JD, Catalano P, Thomas JP *et al.* Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. *J Clin Oncol* 2002; **20**: 3270–5.
6 Colucci G, Giuliani F, Gebbia V *et al.* Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. *Cancer* 2002; **94**: 902–10.
7 Rocha Lima CM, Green MR, Rotche R *et al.* Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. *J Clin Oncol* 2004; **22**: 3776–83.
8 Louvet C, Labianca R, Hammel P *et al.* Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. *J Clin Oncol* 2005; **23**: 3509–16.
9 Oettle H, Richards D, Ramanathan RK *et al.* A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. *Ann Oncol* 2005; **16**: 1639–45.
10 Abou-Alfa GK, Letourneau R, Harker G *et al.* Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. *J Clin Oncol* 2006; **24**: 4441–7.
11 Heinemann V, Quietzsch D, Gieseler F *et al.* Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol* 2006; **24**: 3946–52.
12 Stathopoulos GP, Syrigos K, Aravantinos G *et al.* A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. *Br J Cancer* 2006; **95**: 587–92.
13 Herrmann R, Bodoky G, Ruhstaller T *et al.* Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *J Clin Oncol* 2007; **25**: 2212–7.
14 Van Cutsem E, van de Velde H, Karasek P *et al.* Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. *J Clin Oncol* 2004; **22**: 1430–8.
15 Bramhall SR, Rosemurgy A, Brown PD *et al.* Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. *J Clin Oncol* 2001; **19**: 3447–55.
16 Moore M, Hamm J, Dancey J *et al.* Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2003; **21**: 3296–302.
17 Philip PA, Benedetti J, Fenoglio-Preiser C *et al.* Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [Pca]: SWOG S0205 study. *J Clin Oncol* 2007; **25** (Suppl 18): 199s (Abstract LBA4509).
18 Kindler HL, Niedzwiecki D, Hollis E *et al.* A double-blind, placebo-controlled, randomizes phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A Preliminary Analysis of Cancer and Leukemia Group B (CALGB). *J Clin Oncol* 2007; **25** (Suppl 18): 199s (Abstract 4508).
19 Van Cutsem E, Vervenne WL, Bennouna J *et al.* Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *J Clin Oncol* 2009; **27**: 2231–7.
20 Lynch TJ Jr, Kim ES, Eaby B *et al.* Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. *Oncologist* 2007; **12**: 610–21.
21 Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? *J Clin Oncol* 2005; **23**: 5235–46.
22 Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. *Semin Oncol* 2003; **30**: 3–14.
23 Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. *Oncogene* 2000; **19**: 6102–14.
24 Jost M, Gasparro FP, Jensen PJ *et al.* Keratinocyte apoptosis induced by ultraviolet B radiation and CD95 ligation – differential protection through epidermal growth factor receptor activation and Bcl-x(L) expression. *J Invest Dermatol* 2001; **116**: 860–6.
25 Quon H, Liu F, Cummings B. Potential molecular prognostic markers in head and neck squamous cell carcinomas. *Head Neck* 2001; **23**: 147–59.

doi: 10.1111/j.1349-7006.2010.01810.x

26 Ueda S, Ogata S, Tsuda H *et al.* The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. *Pancreas* 2004; **29**: e1–8.
27 Durkin A, Bloomston PM, Rosemurgy AS *et al.* Defining the role of the epidermal growth factor receptor in pancreatic cancer grown *in vitro*. *Am J Surg* 2003; **186**: 431–6.
28 Moore M, Goldstein D, Hamm J *et al.* Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007; **25**: 1960–6.
29 Kubota K, Nishiwaki Y, Tamura T *et al.* Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. *J Thorac Oncol* 2008; **3**: 1439–45.
30 Dragovich T, Huberman M, Von Hoff DD *et al.* Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. *Cancer Chemother Pharmacol* 2007; **60**: 295–303.
31 Honeywell R, Laan AC, van Groeningen CJ *et al.* The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; **847**: 142–52.
32 Ling J, Fettner S, Lum BL *et al.* Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. *Anticancer Drugs* 2008; **19**: 209–16.
33 Nakamura K, Yamaguchi T, Ishihara T *et al.* Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. *Br J Cancer* 2006; **94**: 1575–9.
34 Tanaka T, Ikeda M, Okusaka T *et al.* Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. *Jpn J Clin Oncol* 2008; **38**: 755–61.
35 Tamiya A, Endo M, Shukuya T *et al.* Features of gemcitabine-related severe pulmonary toxicity patients with pancreatic or biliary tract cancer. *Pancreas* 2009; **38**: 838–40.
36 Bhatia S, Hanna N, Ansari R *et al.* A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. *Lung Cancer* 2002; **38**: 73–7.
37 Ando M, Okamoto I, Yamamoto N *et al.* Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. *J Clin Oncol* 2006; **24**: 2549–56.
38 Kudoh S, Kato H, Nishiwaki N *et al.* Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case–control study. *Am J Respir Crit Care Med* 2008; **177**: 1348–57.
39 Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. *Med Oncol* 2006; **23**: 161–70.
40 Yoneda KY, Shelton DK, Beckett LA *et al.* Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. *J Thorac Oncol* 2007; **2**: 537–43.
41 Wacker B, Nagrani T, Weinberg J *et al.* Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. *Clin Cancer Res* 2007; **13**: 3913–21.
42 Van Cutsem E, Vervenne WL, Bennouna J *et al.* Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. Proc ASCO Gastrointestinal Cancers Symposium, 2009 (Abstr 117). [Cited 16 Feb 2010.] Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10514.
43 Tsao MS, Sakurada A, Cutz JC *et al.* Erlotinib in lung cancer – molecular and clinical predictors of outcome. *N Engl J Med* 2005; **353**: 133–44.
44 Zhu CQ, da Cunha Santos G, Ding K *et al.* Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. *J Clin Oncol* 2008; **28**: 4268–75.
45 Immervoll H, Hoem D, Kugarajh K *et al.* Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. *Virchows Arch* 2006; **448**: 788–96.
46 Lee J, Jang KT, Ki CS *et al.* Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. *Cancer* 2007; **109**: 1561–9.
47 Tzeng CW, Frolov A, Frolova N *et al.* Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. *Surgery* 2007; **141**: 464–9.